Defence Therapeutics Inc.
DTCFF
$0.44
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 121.41% | -55.92% | |||
| Depreciation & Amortization | -43.22% | -15.11% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 126.42% | -57.60% | |||
| Operating Income | -126.42% | 57.60% | |||
| Income Before Tax | -113.83% | 39.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -113.83% | 39.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -113.83% | 39.04% | |||
| EBIT | -126.42% | 57.60% | |||
| EBITDA | -128.53% | 58.10% | |||
| EPS Basic | -111.83% | 39.22% | |||
| Normalized Basic EPS | -112.07% | 34.83% | |||
| EPS Diluted | -111.83% | 39.22% | |||
| Normalized Diluted EPS | -112.07% | 34.83% | |||
| Average Basic Shares Outstanding | 1.14% | 0.03% | |||
| Average Diluted Shares Outstanding | 1.14% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||